Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line

Trial Profile

A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribociclib (Primary) ; Anastrozole; Bevacizumab; Capecitabine; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms RIBBIT
  • Sponsors iOMEDICO AG
  • Most Recent Events

    • 01 Jul 2019 Planned number of patients changed from 160 to 158.
    • 01 Jul 2019 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
    • 01 Jul 2019 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top